raloxifene hydrochloride has been researched along with malondialdehyde in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Arslanoglu, E; Kaya, H; Ozkaya, O; Sezik, M; Ulukaya, E; Yilmaztepe, A | 1 |
| Fadillioglu, E; Kaya, H; Ozgocmen, S; Yilmaz, Z | 1 |
| Genc, H; Kaya, H; Ozbasar, D; Ozkaya, O; Sezik, M; Toros, U; Uzun, H | 1 |
| Aurrekoetxea, I; del Agua, AR; Elorriaga, MA; Guéraud, F; Rodriguez, F; Ruiz-Larrea, MB; Ruiz-Sanz, JI | 1 |
| Akalin, S; Aydin, H; Deyneli, O; Tarçin, O; Tutepe, H; Yavuz, D; Yazici, D; Yüksel, M | 1 |
| Elkhoely, AA; Kabel, AM | 1 |
| Abd-Rabou, AA; Almutairi, FM; Mohamed, MS | 1 |
| Chin, KY; Ima-Nirwana, S; Mohamad, NV | 1 |
3 trial(s) available for raloxifene hydrochloride and malondialdehyde
| Article | Year |
|---|---|
Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women.
Topics: Aged; Erythrocytes; Female; Glutathione Peroxidase; Humans; Malondialdehyde; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Superoxide Dismutase | 2005 |
Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.
Topics: Adult; Aged; Antioxidants; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitonin; Erythrocytes; Etidronic Acid; Female; Humans; Lipid Peroxidation; Malondialdehyde; Middle Aged; Nitric Oxide; Osteoporosis, Postmenopausal; Oxidative Stress; Oxidoreductases; Raloxifene Hydrochloride; Risedronic Acid | 2007 |
Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy.
Topics: Aged; Antioxidants; Female; Humans; Kidney Failure, Chronic; Lipase; Lipoproteins, HDL; Lipoproteins, LDL; Malondialdehyde; Middle Aged; Nitric Oxide; Oxidative Stress; Postmenopause; Raloxifene Hydrochloride; Renal Dialysis; Selective Estrogen Receptor Modulators | 2010 |
5 other study(ies) available for raloxifene hydrochloride and malondialdehyde
| Article | Year |
|---|---|
Involvement of G-463A MPO gene polymorphism in the response of postmenopausal women to hormone therapy.
Topics: Acetylcysteine; alpha-Tocopherol; Antioxidants; Estradiol; Female; Hormone Replacement Therapy; Humans; Intercellular Adhesion Molecule-1; Lipids; Malondialdehyde; Middle Aged; Peroxidase; Polymorphism, Genetic; Postmenopause; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uric Acid | 2011 |
Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats.
Topics: Animals; Aorta; Bone and Bones; Estradiol; Female; Malondialdehyde; Muscle, Smooth, Vascular; Osteoprotegerin; Ovariectomy; Oxidative Stress; Raloxifene Hydrochloride; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger; Selective Estrogen Receptor Modulators; Tibia | 2011 |
Ameliorative potential of fluoxetine/raloxifene combination on experimentally induced breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catalase; Fluoxetine; Humans; Interleukin-6; Malondialdehyde; Raloxifene Hydrochloride; Rats; Superoxide Dismutase; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2016 |
Raloxifene-encapsulated hyaluronic acid-decorated chitosan nanoparticles selectively induce apoptosis in lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Humans; Hyaluronic Acid; Lung Neoplasms; Malondialdehyde; Nanoparticles; Nitric Oxide; Particle Size; Raloxifene Hydrochloride | 2019 |
Therapeutic potential of annatto tocotrienol with self-emulsifying drug delivery system in a rat model of postmenopausal bone loss.
Topics: Absorptiometry, Photon; Animals; Bixaceae; Bone and Bones; Bone Density Conservation Agents; Calcium; Carotenoids; Drug Delivery Systems; Emulsions; Female; Humans; Malondialdehyde; Osteoporosis, Postmenopausal; Ovariectomy; Plant Extracts; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tocotrienols; X-Ray Microtomography | 2021 |